Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | TOP2A | P11388 | 4/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747704 | 0.88 | CYP3A4 (0.60) | CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL4747727 | 0.87 | KCNH2 (0.52) | KCNH2KDM4EGSK3BTOP2ATOP2B | |
| SCHEMBL4747731 | 0.83 | CYP3A4 (0.43) | CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL13469793 | 0.83 | CYP3A4 (0.43) | CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL4747728 | 0.83 | CYP3A4 (0.52) | CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL4747726 | 0.81 | CYP3A4 (0.48) | CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL8131420 | 0.81 | TOP2A (0.44) | CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL8131531 | 0.81 | TOP2A (0.44) | CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL9094282 | 0.81 | TOP2A (0.44) | CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL4712706 | 0.81 | CYP3A4 (0.44) | CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-8222407-B2 | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222407-B2 | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | CYP3A4 153/4885KCNH2 193/4885KDM4E 1244/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | CYP3A4 153/4885KCNH2 193/4885KDM4E 1244/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | CYP3A4 153/4885KCNH2 193/4885KDM4E 1244/4885 |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | PELP1, MLN, SND1 | CYP3A4 3135/4885KCNH2 4321/4885KDM4E 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.